Ling Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ling Wang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Junshan Ruan
Fuzhou Hospital of Traditional Chinese Medicine Affiliated to Fujian University of Traditional Chinese Medicine,School of Pharmacy, Fujian Medical University, Fuzhou, China
4 shared publications Boyang Zhuang
Fujian Center For Drug Evaluation and Monitoring, Fuzhou, China
2 shared publicationsFangqing Cai
The School of Pharmacy, Fujian Medical University, Fuzhou, China
2 shared publicationsJinglin Li
The School of Pharmacy, Fujian Medical University, Fuzhou, China
2 shared publicationsCaiyu Liu
Fujian Univ Tradit Chinese Med, Sch Pharm, Fuzhou, Peoples R China
1 shared publicationChengyang Xu
Fuzhou University Afffliated Provincial Hospital, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
1 shared publication
Latest Publications
- Open Access
- 25 May 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Drug-associated oropharyngeal infection: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Drug-associated oropharyngeal infection represents a common yet frequently overlooked safety concern in clinical practice, potentially increasing patient d
- 25 May 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Open AccessDrug-associated oropharyngeal infection: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Drug-associated oropharyngeal infection represents a common yet frequently overlooked safety concern in clinical practice, potentially increasing patient d
- Open Access
- 24 November 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (2) , 103068
Regulatory mechanism of the oprM gene in colistin resistance of acinetobacter baumannii
- 24 November 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (2) , 103068
Open AccessRegulatory mechanism of the oprM gene in colistin resistance of acinetobacter baumannii
- Open Access
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39433
The relationship between mental health problems and risk of infectious diseases: A Mendelian randomization analysis
The causal effects of mental health problems on the risk of infectious diseases remain vague. Investigating them via observational study is challenging as it presents possible confounding factors. Therefore, the objective of this study was to utilize Mendelian randomization (MR) techniques to evaluate the causal relationship between mental health problems and the risk of infectious diseases. Multivariable MR analyses were performed using genome-wide association data for sleep disorders (N = 216,700), depression (N = 500,199), anxiety (N = 290,361), nervous feelings (N = 450,700), unspecified mental disorder (N = 218,792), pneumonia (N = 486,484), skin and subcutaneous tissue infection (SSTI; N = 218,792), intestinal infectious diseases (IIDs; N = 218,792), urinary tract infection (N = 463,010), and central nervous system (CNS) infections (N = 218,792) among individuals of European ancestry. Independent genetic variants significantly (P < 10−8) associated with each exposure were considered instruments. The primary analysis used an inverse variance-weighted method, followed by a series of sensitivity analyses. Genetically predicted sleep disorders were associated with an increased risk of SSTI (odds ratio [OR], 1.29 [95% confidence interval (CI), 1.05–1.59]; P = .017). Genetically predicted depression was linked with an increased risk of CNS infections (OR, 1.59 [95% CI, 1.00–2.53]; P = .049) and SSTI (1.24 [95% CI, 1.03–1.49]; P = .024). Genetically predicted anxiety was associated with IIDs (OR, 1.19 [95% CI, 1.03–1.37]; P = .017) and SSTI (OR, 1.21 [95% CI, 1.02–1.43]; P = .029). There was no significant causal evidence for genetic prediction of nervous feelings and unspecified mental disorders in IIDs, CNS infections, SSTI, pneumonia, or urinary tract infection. Sensitivity analyses showed that the above causal association estimates were robust. In this MR study, we demonstrated a causal relationship between sleep disorders, depression, anxiety, and the risk of infectious diseases. However, no evidence was found to support causality between nervous feelings, unspecified mental disorders, and the risk of infectious diseases.
- 6 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (36) , e39433
Open AccessThe relationship between mental health problems and risk of infectious diseases: A Mendelian randomization analysis
The causal effects of mental health problems on the risk of infectious diseases remain vague. Investigating them via observational study is challenging as it presents possible confounding factors. Therefore, the objective of this study was to utilize Mendelian randomization (MR) techniques to evaluate the causal relationship between mental health problems and the risk of infectious diseases. Multivariable MR analyses were performed using genome-wide association data for sleep disorders (N = 216,700), depression (N = 500,199), anxiety (N = 290,361), nervous feelings (N = 450,700), unspecified mental disorder (N = 218,792), pneumonia (N = 486,484), skin and subcutaneous tissue infection (SSTI; N = 218,792), intestinal infectious diseases (IIDs; N = 218,792), urinary tract infection (N = 463,010), and central nervous system (CNS) infections (N = 218,792) among individuals of European ancestry. Independent genetic variants significantly (P < 10−8) associated with each exposure were considered instruments. The primary analysis used an inverse variance-weighted method, followed by a series of sensitivity analyses. Genetically predicted sleep disorders were associated with an increased risk of SSTI (odds ratio [OR], 1.29 [95% confidence interval (CI), 1.05–1.59]; P = .017). Genetically predicted depression was linked with an increased risk of CNS infections (OR, 1.59 [95% CI, 1.00–2.53]; P = .049) and SSTI (1.24 [95% CI, 1.03–1.49]; P = .024). Genetically predicted anxiety was associated with IIDs (OR, 1.19 [95% CI, 1.03–1.37]; P = .017) and SSTI (OR, 1.21 [95% CI, 1.02–1.43]; P = .029). There was no significant causal evidence for genetic prediction of nervous feelings and unspecified mental disorders in IIDs, CNS infections, SSTI, pneumonia, or urinary tract infection. Sensitivity analyses showed that the above causal association estimates were robust. In this MR study, we demonstrated a causal relationship between sleep disorders, depression, anxiety, and the risk of infectious diseases. However, no evidence was found to support causality between nervous feelings, unspecified mental disorders, and the risk of infectious diseases.
- Open Access
- 4 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102589
Effectiveness and safety of tetracyclines and quinolones in people with Mycoplasma pneumonia: a systematic review and network meta-analysis
- 4 April 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 71, 102589
Open AccessEffectiveness and safety of tetracyclines and quinolones in people with Mycoplasma pneumonia: a systematic review and network meta-analysis
- 28 February 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (7) , 774-784
Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis
- 28 February 2024
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (7) , 774-784
Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis
- 24 August 2018
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 11 (9) , 917-922
Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication
Background: Dexmedetomidine is a widely used sedative in clinic, which is mainly metabolized by cytochrome P450 2A6 (CYP2A6). Dexmedetomidine was rarely reported for off-label usage of premedication, but lacking relevant pharmacokinetic investigations. Therefore, our study determined the dexmedetomidine pharmacokinetics of CYP2A6*4 allele in Chinese patients pretreated with dexmedetomidine whose mutation frequency of CYP2A6*4 are high, in order to provide clinical references. Methods: Thirty-one elective surgery patients received premedication with 0.5 μg/kg dexmedetomidine via intravenous pump. Their plasma concentrations at multiple time-points and polymorphism of CYP2A6*4 were determined and statistically analyzed. Results: 9 patients were *1/*4 or *4/*4, and 22 patients were *1/*1. The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l−1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l−1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h. No significant pharmacokinetic differences were found among CYP2A6*1/*1, *1/*4, and *4/*4 patients. Conclusions: In Chinese patients pretreated with dexmedetomidine, T1/2β was consistent with that published, but T1/2α, V and Cl were lower. It was unnecessary to consider the mutation when developing the precision regimen of dexmedetomidine.
- 24 August 2018
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 11 (9) , 917-922
Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication
Background: Dexmedetomidine is a widely used sedative in clinic, which is mainly metabolized by cytochrome P450 2A6 (CYP2A6). Dexmedetomidine was rarely reported for off-label usage of premedication, but lacking relevant pharmacokinetic investigations. Therefore, our study determined the dexmedetomidine pharmacokinetics of CYP2A6*4 allele in Chinese patients pretreated with dexmedetomidine whose mutation frequency of CYP2A6*4 are high, in order to provide clinical references. Methods: Thirty-one elective surgery patients received premedication with 0.5 μg/kg dexmedetomidine via intravenous pump. Their plasma concentrations at multiple time-points and polymorphism of CYP2A6*4 were determined and statistically analyzed. Results: 9 patients were *1/*4 or *4/*4, and 22 patients were *1/*1. The main pharmacokinetic parameters were area under curve (AUC) 1396.19 ± 332.47h· ng· l−1, peak blood concentration (Cmax) 495.50 ± 104.90ng· l−1, distribution volume (V) 0.68 ± 0.20 L/kg, clearance (CL) 0.38 ± 0.11 L/h/kg, distribution half-life (t1/2α) 0.05 ± 0.01h, elimination half-life (t1/2β) 2.53 ± 0.04h. No significant pharmacokinetic differences were found among CYP2A6*1/*1, *1/*4, and *4/*4 patients. Conclusions: In Chinese patients pretreated with dexmedetomidine, T1/2β was consistent with that published, but T1/2α, V and Cl were lower. It was unnecessary to consider the mutation when developing the precision regimen of dexmedetomidine.
- 30 April 2011
- Published by Publishing House of Pharmaceutical Care and Research in Pharmaceutical Care and Research
- Vol. 11 (2) , 99-102
Study on the intestinal absorption mechanism of cetirizine
- 30 April 2011
- Published by Publishing House of Pharmaceutical Care and Research in Pharmaceutical Care and Research
- Vol. 11 (2) , 99-102
Study on the intestinal absorption mechanism of cetirizine